BTIG raised the firm’s price target on Cartesian Therapeutics (RNAC) to $44 from $42 and keeps a Buy rating on the shares. The firm cites the ...
Cartesian Therapeutics ( ($RNAC) ) has shared an announcement. On November 13, 2025, Cartesian Therapeutics announced promising initial data from ...
Many precision current source designs are available, but simple arithmetic for component values to tailor them for an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback